Previous 10 | Next 10 |
home / stock / polbf / polbf news
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Pro...
AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection Novel influenza drug targets identified faster and more cost-effectively using AI LONDON, UK / ACCESSWIRE / June 29, 2023 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the ...
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing that work on the company's Oral Vaccine Programme collaboration is now set to move into a new phase. Taking place over three years, the EncOVac Consortium...
Next Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding LONDON, UK / ACCESSWIRE / June 22, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases wi...
(NewsDirect) Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.
LONDON, UK / ACCESSWIRE / May 24, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Exe...
LONDON, UK / ACCESSWIRE / May 11, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces that at the Annual General Meeting held at 12:00pm today, al...
Annual Report & AGM Notice LONDON, UK / ACCESSWIRE / April 12, 2023 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company's Ann...
2023-03-30 09:27:53 ET Poolbeg Pharma press release ( OTCQB:POLBF ): FY Loss of £4.7M Cash balance of £16.2m at year end For further details see: Poolbeg Pharma reports FY results
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full year of operations with £16.2mln. Skillington describes it as a "very h...
News, Short Squeeze, Breakout and More Instantly...
Poolbeg Pharma plc Ord GBP 0.0002 Company Name:
POLBF Stock Symbol:
OTCMKTS Market:
Poolbeg Pharma plc Ord GBP 0.0002 Website:
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntaril...
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the U...
Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medi...